Countries China
Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS &plusm...
March 23, 2026 | News
Alphamab Oncology announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispec...
March 23, 2026 | News
Funding to advance proprietary T-cell engager platforms and pipeline of highly differentiated T-cell engager therapies targeting solid tumors and autoi...
March 20, 2026 | News
IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's propri...
March 19, 2026 | News
-Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammat...
March 18, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease...
March 18, 2026 | News
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has rec...
March 17, 2026 | News
Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative du...
March 16, 2026 | News
Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational N...
March 16, 2026 | News
Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, announced the approval of its Investigational New Drug (IND) application f...
March 16, 2026 | News
The preceding decade was marked by rapid growth and robust policy backing; however, the landscape has fundamentally evolved. Research and development expen...
March 13, 2026 | Opinion | By By Adam Zhang Yu, Founder & CEO, Collabrium Partners
Most Read
Bio Jobs
News